Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00125528 · ClinicalTrials.gov registry record · Phase 2

D-cycloserine in the Management of Chronic Low Back Pain

A Phase 2 study of Pain and Low Back Pain, sponsored by Thomas J. Schnitzer.

Completed
Registry status
Phase 2
Development phase
41
Enrollment target
1
Study location

NCT00125528 is a Phase 2 study of Pain and Low Back Pain that has completed, run by Thomas J. Schnitzer. The registered enrollment target is 41 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00125528, a Phase 2 study of Pain and Low Back Pain, has completed, sponsored by Thomas J. Schnitzer.

COMPLETED
Registry status
Phase 2
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

Pre-clinical studies in rats suggest that D-cycloserine (DCS) is effective in the management of chronic neuropathic pain. This pilot study will attempt to determine the effect of D-cycloserine in the treatment of chronic low back pain. Other aims of this study are to determine the safety of D-cycloserine in the treatment of chronic low back pain and to determine which pain measurement scales are best at measuring the efficacy of treatment.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG D-cycloserine

Study Locations (1)

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2012-07
Est. Completion 2014-11
Phase Phase 2

Sponsor

Thomas J. Schnitzer

5 total trials

What the Registry Record Tells You About NCT00125528

The ClinicalTrials.gov registry entry for NCT00125528 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (87% lower). The listed sponsor is Thomas J. Schnitzer, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00125528 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00125528 about?

NCT00125528 is a clinical study titled "D-cycloserine in the Management of Chronic Low Back Pain". Pre-clinical studies in rats suggest that D-cycloserine (DCS) is effective in the management of chronic neuropathic pain. This pilot study will attempt to determine the effect of D-cycloserine in the treatment of chronic low back pain. Other aims of this study are to determine the safety of D-cyclos...

What is the current status of trial NCT00125528?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2012-07. Estimated completion is 2014-11.

What conditions does trial NCT00125528 study?

This clinical trial studies the following conditions: Pain, Low Back Pain.

What interventions are being tested in trial NCT00125528?

The interventions under investigation include: placebo (DRUG), D-cycloserine (DRUG).

Who is sponsoring clinical trial NCT00125528?

This trial is sponsored by Thomas J. Schnitzer, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00125528 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.